Wire Stories
Shaperon Enrolls Its First Patient in Phase 2 U.S. Clinical Trial for Atopic Dermatitis Therapy ‘Nugel’
210 Patients With Multi-Racial Atopic Dermatitis…Phase 2 Clinical Trial Begins CAMBRIDGE, Mass. & SEOUL, South Korea–(BUSINESS WIRE)–Shaperon, Inc. (Kosdaq: 378800), a biotechnology...